How GLP‑1 Agonists Are Transforming Obesity Care: A 2026 Guide
Semaglutide and Tirzepatide Deliver Up to 22% Weight Loss in Landmark Trials - A New Era for Obesity Treatment Large-scale Phase III studies published between 2021 and 2023 showed that once-weekly GLP-1 agonists can trim more than one-fifth of body weight in less than a year, outpacing most diet-exercise regimens.